MK-4830
- Generic Name
- MK-4830
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
- Associated Conditions
- -
- Associated Therapies
- -
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT04165083
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center ( Site 0033), Baltimore, Maryland, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital ( Site 0003), Boston, Massachusetts, United States
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 442
- Registration Number
- NCT03564691
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 0033), Toronto, Ontario, Canada
🇺🇸Seattle Cancer Care Alliance ( Site 0010), Seattle, Washington, United States
🇺🇸University of California at San Francisco ( Site 0004), San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.